dihydrocodeine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
886 125-28-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dihydrocodeine
  • codhydrine
  • cohydrin
  • dehacodin
  • dihydroneopine
  • hydrocodeine
  • hydrocodin
  • dihydrocodeine bitartrate
  • parzone bitartrate
  • dihydrocodeine phosphate
  • Molecular weight: 301.39
  • Formula: C18H23NO3
  • CLOGP: 1.26
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 41.93
  • ALOGS: -2.10
  • ROTB: 1
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.15 g O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 20 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.07 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4.21 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.42 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 222 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.033 Moderate 0.72
caco2-efflux Caco-2 efflux ratio (BA/AB) 1.563 Moderate 0.72
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 14.060 10^-6 cm/s Moderate 0.72
dh-clint Dog hepatocyte intrinsic clearance 7.145 uL/min/10^6 cells Moderate 0.72
dppb Dog plasma protein binding (% unbound) 70.190 % Moderate 0.72
fcs-ppb Fetal calf serum protein binding (% unbound) 80.470 % Moderate 0.72
herg hERG pIC50 4.776 pIC50 Moderate 0.72
hh-clint Human hepatocyte intrinsic clearance 1.253 uL/min/10^6 cells Moderate 0.72
hlm-clint Human liver microsomal intrinsic clearance 6.124 uL/min/mg protein Moderate 0.72
hppb Human plasma protein binding (% unbound) 68.730 % Moderate 0.72
kinase-safety-class ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK3,MAPK10,MAPK7,MET,NTRK2,PDK2,PDK4,PIM2,PRKDC,TEK,TGFBR1,ZAP70 26
kinase-selectivity-class EIF2AK3 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 2.742 Moderate 0.72
mh-clint Mouse hepatocyte intrinsic clearance 20.324 Moderate 0.72
mppb Mouse plasma protein binding (% unbound) 65.740 Moderate 0.72
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 12.764 Moderate 0.72
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 81.400 % Moderate 0.72
rh-clint Rat hepatocyte intrinsic clearance 35.400 uL/min/10^6 cells Moderate 0.72
rh-fuinc Rat hepatocyte fraction unbound in incubation 85.370 % Moderate 0.72
rppb Rat plasma protein binding (% unbound) 65.580 % Moderate 0.72
solubility-dd Solubility at pH 7.4 in DMSO 926.830 uM Moderate 0.72

Approvals:

DateAgencyCompanyOrphan
July 7, 1958 FDA CARACO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 101.44 22.18 94 4222 287752 90336379
Acute kidney injury 89.24 22.18 92 4224 320295 90303836
Neutropenic sepsis 80.98 22.18 31 4285 18099 90606032
Congenital thrombocytopenia 78.78 22.18 11 4305 55 90624076
Hydronephrosis 54.63 22.18 21 4295 12381 90611750
Abdominal pain 52.05 22.18 78 4238 395643 90228488
Toxic leukoencephalopathy 50.67 22.18 11 4305 842 90623289
Intestinal pseudo-obstruction 47.27 22.18 11 4305 1152 90622979
Toxic encephalopathy 46.59 22.18 17 4299 8682 90615449
Blood creatine phosphokinase 46.46 22.18 8 4308 178 90623953
Heart rate 44.36 22.18 8 4308 234 90623897
Limbic encephalitis 42.78 22.18 8 4308 287 90623844
Overflow diarrhoea 41.81 22.18 7 4309 131 90624000
Perforation 41.38 22.18 11 4305 1983 90622148
Sepsis 40.06 22.18 46 4270 179768 90444363
Symptom masked 38.05 22.18 9 4307 1012 90623119
Pancreatitis chronic 37.52 22.18 11 4305 2832 90621299
Overdose 36.23 22.18 41 4275 157668 90466463
Poisoning deliberate 36.09 22.18 17 4299 16469 90607662
Brain oedema 35.23 22.18 17 4299 17368 90606763
Blood uric acid abnormal 33.95 22.18 6 4310 156 90623975
Colitis 32.90 22.18 27 4289 69915 90554216
Acquired cystic kidney disease 32.34 22.18 5 4311 55 90624076
Terminal ileitis 31.27 22.18 8 4308 1242 90622889
Peritonitis 30.34 22.18 16 4300 19689 90604442
Biliary sepsis 28.08 22.18 7 4309 979 90623152
Abnormal loss of weight 28.08 22.18 11 4305 6812 90617319
Oesophageal candidiasis 28.07 22.18 11 4305 6818 90617313
Colitis ischaemic 27.86 22.18 13 4303 12333 90611798
Drug ineffective 26.17 22.18 17 4299 1384281 89239850
Cytomegalovirus infection 25.87 22.18 16 4300 26586 90597545
Brain herniation 25.47 22.18 9 4307 4191 90619940
Urinary retention 25.30 22.18 18 4298 37726 90586405
Blood creatinine increased 24.36 22.18 27 4289 101359 90522772
Large intestine perforation 24.33 22.18 11 4305 9701 90614430
Vomiting 23.95 22.18 87 4229 788206 89835925
Constipation 23.14 22.18 45 4271 280350 90343781
Intentional overdose 22.56 22.18 25 4291 93809 90530322

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 94.90 23.36 95 2751 229041 42389448
Overdose 67.67 23.36 56 2790 105208 42513281
Autoscopy 53.44 23.36 10 2836 254 42618235
Gas poisoning 49.22 23.36 8 2838 86 42618403
Femoral nerve palsy 37.31 23.36 6 2840 60 42618429
Drug dependence 31.00 23.36 21 2825 29073 42589416
Sensory loss 30.83 23.36 12 2834 5212 42613277
Formication 28.86 23.36 9 2837 2032 42616457
Intentional product misuse 27.90 23.36 27 2819 61873 42556616
Tandem gait test abnormal 25.56 23.36 4 2842 33 42618456
Substance abuse 24.67 23.36 12 2834 8893 42609596
Alcoholic liver disease 24.33 23.36 6 2840 571 42617918
Lethargy 24.09 23.36 22 2824 46868 42571621
Upper gastrointestinal haemorrhage 23.41 23.36 18 2828 30281 42588208

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Toxicity to various agents 148.14 19.29 167 6885 480388 110101859
Acute kidney injury 76.07 19.29 141 6911 635289 109946958
Overdose 73.02 19.29 82 6970 233712 110348535
Neutropenic sepsis 62.20 19.29 33 7019 30713 110551534
Gas poisoning 49.33 19.29 8 7044 89 110582158
Heart rate 40.50 19.29 8 7044 285 110581962
Toxic leukoencephalopathy 40.48 19.29 11 7041 1606 110580641
Perforation 39.25 19.29 11 7041 1799 110580448
Blood creatine phosphokinase 39.24 19.29 8 7044 335 110581912
Abnormal loss of weight 39.06 19.29 17 7035 10240 110572007
Hydronephrosis 38.49 19.29 21 7031 20644 110561603
Abdominal pain 38.20 19.29 94 6958 512895 110069352
Drug ineffective 37.10 19.29 26 7026 1520514 109061733
Overflow diarrhoea 36.29 19.29 7 7045 220 110582027
Femoral nerve palsy 35.59 19.29 6 7046 86 110582161
Toxic encephalopathy 35.56 19.29 18 7034 15196 110567051
Drug dependence 33.90 19.29 27 7025 49993 110532254
Intentional product misuse 33.78 19.29 42 7010 132862 110449385
Substance abuse 32.85 19.29 16 7036 12447 110569800
Limbic encephalitis 32.42 19.29 8 7044 800 110581447
Sepsis 32.16 19.29 67 6985 327279 110254968
Blood uric acid abnormal 31.57 19.29 7 7045 439 110581808
Acquired cystic kidney disease 30.64 19.29 5 7047 58 110582189
Asphyxia 28.02 19.29 15 7037 14200 110568047
Respiratory depression 27.71 19.29 20 7032 31981 110550266
Upper gastrointestinal haemorrhage 27.62 19.29 24 7028 50072 110532175
Somnolence 27.04 19.29 59 6993 297390 110284857
Pancreatitis chronic 25.88 19.29 10 7042 4455 110577792
Premature baby 25.07 19.29 10 7042 4845 110577402
Alcoholic liver disease 24.65 19.29 6 7046 567 110581680
Poisoning deliberate 24.05 19.29 17 7035 26314 110555933
Brain oedema 23.71 19.29 18 7034 31080 110551167
Tandem gait test abnormal 23.09 19.29 4 7048 68 110582179
Constipation 22.91 19.29 62 6990 357724 110224523
Terminal ileitis 22.35 19.29 7 7045 1677 110580570
Faecaloma 21.96 19.29 13 7039 14895 110567352
Biliary sepsis 21.73 19.29 7 7045 1836 110580411
Urinary retention 20.95 19.29 24 7028 69659 110512588
Colitis 20.82 19.29 29 7023 102294 110479953
Peritonitis 20.82 19.29 17 7035 32590 110549657
Vomiting 20.51 19.29 113 6939 910562 109671685
Intentional overdose 20.45 19.29 33 7019 132468 110449779
Cholestasis of pregnancy 19.94 19.29 6 7046 1259 110580988
Colitis ischaemic 19.88 19.29 13 7039 17737 110564510
Substance use 19.62 19.29 7 7045 2499 110579748
Drug abuse 19.41 19.29 38 7014 177373 110404874

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N02AA08 NERVOUS SYSTEM
ANALGESICS
OPIOIDS
Natural opium alkaloids
ATC N02AA58 NERVOUS SYSTEM
ANALGESICS
OPIOIDS
Natural opium alkaloids
ATC N02AJ01 NERVOUS SYSTEM
ANALGESICS
OPIOIDS
Opioids in combination with non-opioid analgesics
ATC N02AJ02 NERVOUS SYSTEM
ANALGESICS
OPIOIDS
Opioids in combination with non-opioid analgesics
ATC N02AJ03 NERVOUS SYSTEM
ANALGESICS
OPIOIDS
Opioids in combination with non-opioid analgesics
MeSH PA D000700 Analgesics
MeSH PA D000701 Analgesics, Opioid
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D009294 Narcotics
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
FDA MoA N0000175684 Full Opioid Agonists
FDA EPC N0000175690 Opioid Agonist
CHEBI has role CHEBI:35480 analgesic

Related Drugs by ATC class:

N02AA Natural opium alkaloids 8 drugs
codeinehydromorphonemorphinenaloxonenaltrexonenicomorphineoxycodoneoxymorphone
N02AJ Opioids in combination with non-opioid analgesics 9 drugs
acetylsalicylic acidcelecoxibcodeinedexketoprofenhydrocodoneibuprofenoxycodoneparacetamoltramadol

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pain indication 22253000
Cough indication 49727002
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Nasal congestion indication 68235000
Rhinitis indication 70076002 DOID:4483
Common cold indication 82272006 DOID:10459
Necrotizing enterocolitis in fetus OR newborn contraindication 2707005
Ocular hypertension contraindication 4210003 DOID:9282
Suicidal thoughts contraindication 6471006
Dependent drug abuse contraindication 6525002
Alcoholism contraindication 7200002
Alcohol withdrawal delirium contraindication 8635005
Peptic ulcer contraindication 13200003 DOID:750
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Asthenia contraindication 13791008
Constipation contraindication 14760008 DOID:2089
Mood swings contraindication 18963009
Myocardial infarction contraindication 22298006 DOID:5844
Inflammatory bowel disease contraindication 24526004 DOID:0050589
Ventricular tachycardia contraindication 25569003
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Hypercapnia contraindication 29596007
Dehydration contraindication 34095006
Hyperthyroidism contraindication 34486009 DOID:7998
Acute hepatitis contraindication 37871000
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Gastrointestinal ulcer contraindication 40845000
Hypothyroidism contraindication 40930008 DOID:1459
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Acidosis contraindication 51387008
Vitamin K deficiency contraindication 52675005 DOID:11249
Nasal polyp contraindication 52756005
Coronary arteriosclerosis contraindication 53741008 DOID:3393
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Ulcerative colitis contraindication 64766004 DOID:8577
Arterial thrombosis contraindication 65198009
Substance abuse contraindication 66214007
Benign intracranial hypertension contraindication 68267002 DOID:11459
Poisoning by acetaminophen contraindication 70273001
Agoraphobia contraindication 70691001 DOID:593
Arteriosclerotic vascular disease contraindication 72092001
Diabetes mellitus contraindication 73211009 DOID:9351
Factor II deficiency contraindication 73975000
Reye's syndrome contraindication 74351001 DOID:14525
Gastrointestinal hemorrhage contraindication 74474003
Urethral stricture contraindication 76618002
Thrombotic thrombocytopenic purpura contraindication 78129009 DOID:10772
Decreased respiratory function contraindication 80954004
Injury of head contraindication 82271004
Chronic idiopathic constipation contraindication 82934008
Cor pulmonale contraindication 83291003 DOID:8515
Pulmonary emphysema contraindication 87433001
Gout contraindication 90560007 DOID:13189
Kidney disease contraindication 90708001 DOID:557
Hemophilia contraindication 90935002
Anemia due to enzyme deficiency contraindication 111577008
Acute abdominal pain contraindication 116290004
Gastrointestinal obstruction contraindication 126765001
Neoplasm of brain contraindication 126952004 DOID:1319
von Willebrand disorder contraindication 128105004 DOID:12531
Seizure disorder contraindication 128613002
Drug-induced psychosis contraindication 191483003 DOID:1742
Obsessive-compulsive disorder contraindication 191736004 DOID:10933
Insomnia contraindication 193462001
Partial atrioventricular block contraindication 195039008
Acute pancreatitis contraindication 197456007 DOID:2913
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Morbid obesity contraindication 238136002 DOID:11981
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Exacerbation of asthma contraindication 281239006
Pregnancy, function contraindication 289908002
Lesion of brain contraindication 301766008
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Panic disorder contraindication 371631005 DOID:594
Coma contraindication 371632003
Primary adrenocortical insufficiency contraindication 373662000
Operation on gastrointestinal tract contraindication 386621005
Hypoxia contraindication 389086002
Angle-closure glaucoma contraindication 392291006 DOID:13550
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Myocardial infarction in recovery phase contraindication 418044006
Central nervous system depression contraindication 418072004
Dysfunction of sphincter of Oddi contraindication 430887001
Hypertensive urgency contraindication 443482000
Acute erosive gastritis contraindication 444926003




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.22 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Mu-type opioid receptor GPCR AGONIST CHEMBL CHEMBL

External reference:

IDSource
4019720 VUID
N0000147812 NUI
D01481 KEGG_DRUG
5965-13-9 SECONDARY_CAS_RN
104966 RXNORM
4018062 VANDF
4019720 VANDF
C0058056 UMLSCUI
CHEBI:135276 CHEBI
CHEMBL1595 ChEMBL_ID
CHEMBL2062266 ChEMBL_ID
DB01551 DRUGBANK_ID
C014481 MESH_SUPPLEMENTAL_RECORD_UI
5284543 PUBCHEM_CID
7594 IUPHAR_LIGAND_ID
728 INN_ID
24204-13-5 SECONDARY_CAS_RN
N9I9HDB855 UNII
4599 MMSL
d03168 MMSL
001557 NDDF
004420 NDDF
004421 NDDF
322538006 SNOMEDCT_US
387322000 SNOMEDCT_US
57811004 SNOMEDCT_US
N9I9HDB855 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Acetaminophen, Caffeine, Dihydrocodeine Bitartrate HUMAN PRESCRIPTION DRUG LABEL 3 42195-840 CAPSULE 16 mg ORAL ANDA 28 sections
Dihydrocodeine Bitartrate, Acetaminophen and Caffeine HUMAN PRESCRIPTION DRUG LABEL 3 54868-5900 TABLET 32 mg ORAL ANDA 20 sections
Trezix HUMAN PRESCRIPTION DRUG LABEL 3 63187-705 CAPSULE 16 mg ORAL ANDA 22 sections
Trezix HUMAN PRESCRIPTION DRUG LABEL 3 66992-840 CAPSULE 16 mg ORAL ANDA 23 sections